Advertisement Pharmaceutical Business review -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
March 9, 2026

BMS gains FDA approval for Sotyktu in psoriatic arthritis treatment

Bristol Myers Squibb (BMS) has received the US Food and Drug Administration (FDA) approval for Sotyktu (deucravacitinib), an oral selective tyrosine kinase 2 (TYK2) inhibitor, to treat adults with active psoriatic arthritis (PsA).

Sotyktu has five years of clinical safety and efficacy data in patients with moderate-to-severe plaque psoriasis. Credit: 89stocker / Shutterstock.com.